Written by
Mustafa Çelik
Mustafa Çelik Liv Hospital Content Team
Medically reviewed by

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
...
Views
Read Time
...
views
Read Time
Pancreatic Cancer: Vital Common Tumor Types
Pancreatic Cancer: Vital Common Tumor Types 4

Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic tumor. It makes up more than 92% of all pancreatic cancer cases.

It greatly boosts survival chances for PDAC patients. We are committed to providing exceptional care and support for patients from around the world.

The outlook for carcinoma pancreas prognosis heavily relies on when it’s found. That’s why finding it early is so important. We use the newest medical tech and treatments to help our patients.

Key Takeaways

  • PDAC is the most common type of pancreatic tumor.
  • Early detection is key for better survival rates.
  • Liv Hospital offers full support for international patients.
  • The prognosis for carcinoma pancreas depends on the stage at diagnosis.
  • We use the latest medical tech and treatments.

The Landscape of Pancreatic Cancer

The Landscape of Pancreatic Cancer
Pancreatic Cancer: Vital Common Tumor Types 5

To understand pancreatic cancer, we must first know about the pancreas. It’s a vital organ behind the stomach, key to digestion and metabolism. It has different types of tissue.

The Pancreas: Structure and Function

The pancreas has various cells, each with its own job. Most of it is made up of exocrine cells. These cells make digestive enzymes to break down food.

The pancreas also has endocrine cells. These cells form clusters called islets of Langerhans. They produce hormones like insulin and glucagon to control blood sugar.

Knowing how the pancreas works helps us understand pancreatic cancer. Problems in the exocrine or endocrine parts can cause tumors.

Types of Pancreatic Tissue and Tumors

Pancreatic cancer includes many types of tumors. The most common is pancreatic ductal adenocarcinoma (PDAC). It starts in the exocrine part of the pancreas.

Other types are pancreatic neuroendocrine tumors (PNETs). These come from endocrine cells and can be either benign or malignant.

Each tumor type needs its own treatment plan. Personalized care is key for patients with pancreatic cancer. We tailor treatments based on the type and stage of their disease.

Pancreatic Ductal Adenocarcinoma: The Predominant Form

Pancreatic Ductal Adenocarcinoma: The Predominant Form
Pancreatic Cancer: Vital Common Tumor Types 6

Pancreatic cancer is mostly made up of pancreatic ductal adenocarcinoma (PDAC). This type is aggressive and common. At Liv Hospital, we understand PDAC well to give our patients the best care.

Definition and Prevalence Statistics

Pancreatic ductal adenocarcinoma (PDAC) starts in the pancreas’s ductal cells. It grows fast and is hard to treat. Studies show PDAC makes up over 92% of pancreatic cancers.

PDAC is a big worry worldwide. It’s deadly, and its numbers are high. This is because of genetics, environment, and lifestyle.

Key statistics on PDAC prevalence include:

  • Over 92% of pancreatic cancer cases are diagnosed as PDAC.
  • PDAC is more common in older adults, with most cases diagnosed between the ages of 65 and 74.
  • The incidence of PDAC is slightly higher in men than in women.

Why PDAC Constitutes Over 92% of Cases

Several factors make PDAC the main type of pancreatic cancer. The pancreas’s ductal cells are more likely to turn cancerous. This is due to smoking, genetics, and chronic pancreatitis.

Also, symptoms often show up late. There’s no good screening yet. This makes treatment harder. We stress the need for early detection and research to help patients.

“Understanding the molecular underpinnings of PDAC is key for new treatments and better survival chances.”

Liv Hospital Oncology Team

The outlook for PDAC patients is tough. The five-year survival rate is low. But, new treatments like surgery, chemotherapy, and radiation are giving hope.

We want to improve survival rates and quality of life for our patients.

Epidemiology and Impact of Pancreatic Cancer

Looking into pancreatic cancer’s impact means checking its incidence and mortality rates. It’s a major health issue because of its high death rate and growing number of cases. We’ll dive into the latest numbers and trends to grasp this disease better.

Current Incidence and Mortality Rates

Pancreatic cancer is a top killer among cancer deaths globally. In the U.S., it causes a lot of new cases and deaths each year. Recent data shows it affects some groups more, making targeted awareness and screening key.

The numbers for pancreatic cancer’s incidence and mortality are scary. It’s often found late, which makes its death rate high. We need to see these numbers to grasp how serious this issue is.

  • Pancreatic cancer is among the top 10 most common cancers in the United States.
  • The incidence rate has been increasing over the past few decades.
  • Mortality rates remain high due to late diagnosis and limited treatment options.

Projected Statistics for 2025 and Beyond

Experts predict pancreatic cancer’s incidence and mortality will keep going up. It’s expected that 67,440 Americans will be diagnosed with pancreatic cancer in 2025, and over 51,980 deaths will occur. These numbers highlight the need for more awareness, early detection, and better treatments.

We’re committed to tackling pancreatic cancer’s challenges. Our team is working hard to improve patient care and outcomes.

Understanding pancreatic cancer’s epidemiology and impact helps us tackle its challenges. Our goal is to give accurate, timely info to patients, caregivers, and healthcare providers. This way, we can fight this disease more effectively.

Risk Factors for Developing Pancreatic Cancer

Knowing the risk factors for pancreatic cancer is key for early detection and prevention. This way, we can offer targeted screening and preventive steps.

Genetic and Hereditary Factors

Genetic mutations are a big deal in pancreatic cancer. If you have a family history of the disease, you’re at higher risk. This is true if you have a first-degree relative, like a parent or sibling, who had it.

Some genetic syndromes also raise your risk. These include:

  • BRCA2 mutations
  • Peutz-Jeghers syndrome
  • Familial atypical multiple mole melanoma syndrome
  • Hereditary pancreatitis

We suggest genetic counseling for those with a big family history.

Age, Gender, and Ethnicity Considerations

Age is a big risk factor, with most cases in people over 65. Men are slightly more likely to get it than women. Also, African Americans have a higher risk than other ethnic groups in the U.S.

Lifestyle and Environmental Influences

Lifestyle and environment also affect your risk. Key factors include:

  • Smoking: Smoking doubles your risk compared to non-smokers.
  • Obesity: Being overweight or obese increases your risk.
  • Diet: Eating a lot of red and processed meats and not enough fruits and veggies may raise your risk.
  • Occupational exposure: Working with certain chemicals, like pesticides and dyes, can also increase your risk.

By knowing these risk factors, we can spot high-risk individuals early. At Liv Hospital, we’re dedicated to giving them the best care and support.

Recognizing the Warning Signs

It’s important to know the warning signs of pancreatic cancer early. This can lead to better treatment and survival chances. Pancreatic ductal adenocarcinoma (PDAC), the most common type, often shows symptoms that are not clear.

Early and Late-Stage Symptoms of PDAC

The symptoms of PDAC change with the disease’s stage. In the early stages, you might feel:

  • Vague abdominal pain that spreads to the back
  • Unexplained weight loss because of less pancreatic enzymes
  • Loss of appetite and feeling full quickly

As the disease gets worse, symptoms become more obvious, such as:

  1. Jaundice (yellow skin and eyes) from blocked bile ducts
  2. Dark urine and pale stools
  3. Diabetes or changes in blood sugar levels

Why Pancreatic Cancer Often Remains Silent

Pancreatic cancer is called a “silent disease” because it often doesn’t show symptoms until it’s too late. Several reasons explain this:

  • The pancreas is deep in the abdomen, so tumors can grow big before symptoms appear.
  • The symptoms of pancreatic cancer are often not clear and can be mistaken for other, less serious issues.
  • It’s hard to find pancreatic cancer early because there are no good screening tests for everyone.

With less than 20% of patients being able to have surgery at diagnosis, finding it early is key. We need to spread the word about the signs and symptoms of pancreatic cancer to help more people.

The Diagnostic Process

We start with initial checks and cutting-edge technology. Accurate diagnosis is key for the right treatment.

Initial Assessment and Blood Biomarkers

The first step is a thorough check-up, including your medical history and physical exam. Blood tests look for biomarkers that might show pancreatic cancer. CA 19-9 is one such biomarker often found in pancreatic adenocarcinoma.

Biomarker

Significance

Clinical Utility

CA 19-9

Elevated in pancreatic cancer

Monitoring treatment response

CEA

May be elevated in various cancers

Assessing prognosis

Advanced Imaging Techniques

Advanced imaging is key for diagnosing and staging pancreatic cancer. CT scans, MRI, and Endoscopic Ultrasound (EUS) give us detailed images. They help spot tumors and check if they can be removed.

Biopsy Methods and Molecular Testing

A biopsy is vital to confirm pancreatic cancer. We use Fine-needle aspiration (FNA) guided by EUS for tissue samples. Molecular testing on these samples helps find genetic mutations. This guides treatment and gives insights into the cancer’s outlook.

By combining these methods, we can accurately diagnose pancreatic adenocarcinoma. Then, we create a treatment plan tailored for each patient.

Staging and Classification Systems

Accurate staging is key for pancreatic cancer patients. It helps figure out the prognosis and treatment plan. Staging looks at the tumor size, lymph node spread, and metastasis.

We use different systems to classify pancreatic cancer. The TNM classification is one of the most common.

TNM Classification for Pancreatic Cancer

The TNM system, made by the American Joint Committee on Cancer (AJCC), stages pancreatic cancer. It looks at three main parts:

  • T (Tumor): This part shows the tumor size and how far it has grown.
  • N (Node): It checks if the cancer has reached nearby lymph nodes.
  • M (Metastasis): This part shows if the cancer has spread to distant parts of the body.

By combining these parts, we can find the overall stage of pancreatic cancer. This helps plan the treatment.

Resectability Categories and Their Implications

Another important system for pancreatic cancer is based on resectability. It tells us if the tumor can be surgically removed.

The resectability categories are:

  1. Resectable: Tumors that can be completely removed surgically.
  2. Borderline Resectable: Tumors that might be removable, but it’s not sure how far the disease has spread.
  3. Locally Advanced: Tumors that have spread locally but can’t be removed.
  4. Metastatic: Tumors that have spread to distant organs.

Knowing these categories helps us tailor the treatment plan. This improves outcomes for each patient.

Experts say, “The accurate classification of pancreatic cancer is essential for selecting the most appropriate treatment strategy and improving patient outcomes.” (Expert Opinion)

Comprehensive Treatment Approaches

Managing pancreatic cancer requires a detailed treatment plan. This plan combines different therapies based on each patient’s needs. Our team uses a team effort to create personalized care plans.

Surgical Interventions and Eligibility

Surgery is key in treating pancreatic cancer, aiming for a cure in early stages. Surgical resection is considered for patients with tumors that can be removed. We check if a patient is eligible through advanced imaging and team discussions.

  • Preoperative evaluation to assess tumor resectability
  • Surgical techniques, including pancreaticoduodenectomy (Whipple procedure)
  • Postoperative care and management of possible complications

Chemotherapy Regimens and Protocols

Chemotherapy is essential in treating pancreatic cancer, used at various disease stages. We use evidence-based chemotherapy regimens, including treatments before and after surgery, to enhance results.

  1. FOLFIRINOX for locally advanced or metastatic disease
  2. Gemcitabine-based regimens for advanced pancreatic cancer
  3. Clinical trials for new chemotherapy agents and combinations

Radiation Therapy and Combined Modalities

Radiation therapy is a vital part of pancreatic cancer treatment, often paired with chemotherapy. We use advanced radiation methods, like stereotactic body radiation therapy (SBRT), for precise and effective treatment.

We tailor the use of radiation therapy with other treatments, like chemotherapy and surgery, based on each patient’s disease and health.

Our goal is to improve outcomes for pancreatic cancer patients. We aim to increase both survival rates and quality of life.

Why Pancreatic Cancer Is So Deadly

To understand why pancreatic cancer is deadly, we need to look at its aggressive nature, early detection challenges, and how it resists treatment. The most common and deadly form of pancreatic cancer is called pancreatic ductal adenocarcinoma (PDAC).

Biological Aggressiveness of PDAC

PDAC grows fast and spreads early, making treatment hard. Its aggressive behavior comes from genetic and molecular changes that help tumors grow and resist treatment.

The main reasons for PDAC’s aggressiveness are:

  • Many mutations and genetic instability
  • Quick invasion and spread to nearby tissues and lymph nodes
  • Resistance to cell death and survival pathways

Challenges in Early Detection

Finding pancreatic cancer early is tough because its symptoms are not specific and there’s no good screening for everyone. Most patients are diagnosed too late when the cancer can’t be removed.

The big hurdles in early detection are:

  1. No specific biomarkers for early disease
  2. Non-specific symptoms that can be mistaken for other conditions
  3. Not enough screening for those at high risk

Treatment Resistance Mechanisms

Pancreatic cancer is hard to treat because it resists common therapies like chemotherapy and radiation. Several factors make it resistant, including a dense tumor environment that blocks drugs.

The main reasons for treatment resistance are:

  • A dense tumor environment that blocks drug delivery
  • Survival pathways and mechanisms that prevent cell death
  • Presence of stem cells that lead to recurrence and spread

Knowing these factors is key to finding better treatments and improving survival rates. At Liv Hospital, we’re working hard to understand and treat pancreatic cancer better through advanced care and research.

Survival Rates and Prognostic Factors

Survival rates for pancreatic cancer are a big worry. This is because it’s often found late and grows fast. Knowing how to predict outcomes is key for both patients and doctors.

Current Statistics on Survival Rates

The five-year survival rate for pancreatic cancer is about 13%. This shows how hard it is to catch and treat this disease early.

Key Survival Rate Statistics:

  • Localized pancreatic cancer: 44% five-year survival rate
  • Regional pancreatic cancer: 15% five-year survival rate
  • Distant metastatic pancreatic cancer: 3% five-year survival rate

Factors Influencing Patient Outcomes

Many things can change how well a patient does with pancreatic cancer. These include:

  1. Stage at Diagnosis: Finding it early can really help.
  2. Tumor Resectability: If the tumor can be removed, patients do better.
  3. Patient’s Overall Health: Other health problems can affect treatment and survival.
  4. Genetic Mutations: Some genetic changes can make the cancer grow faster or respond differently to treatment.

A top oncologist says, “Thanks to new treatments, survival rates for pancreatic cancer have gone up a bit. But finding it early is the best way to improve these rates.”

“New ways to cut, treat, and kill cancer cells have helped some patients. But because it’s often found late, the survival rate is not much better.”

Our team creates custom treatment plans. This helps improve patient outcomes and life quality.

Beyond PDAC: Other Pancreatic Tumors

There are many pancreatic tumors beyond PDAC, each with its own traits and treatment methods. PDAC is the most common pancreatic cancer. But, other tumors also affect the pancreas, bringing their own set of challenges and treatment plans.

Pancreatic Neuroendocrine Tumors (PNETs)

PNETs are rare pancreatic tumors that start in hormone-producing cells. They have a better outlook than PDAC, mainly if caught early. PNETs can either work (functioning) or not work (non-functioning), based on hormone production.

Key characteristics of PNETs include:

  • Originate from neuroendocrine cells
  • Can be benign or malignant
  • May produce hormones leading to various symptoms
  • Often have a better prognosis than PDAC

Cystic Neoplasms and Rare Pancreatic Malignancies

Cystic neoplasms are pancreatic tumors that can be benign, pre-cancerous, or cancerous. They have a cystic structure and can have different cancer risks. Other rare cancers include acinar cell carcinoma, pancreatoblastoma, and solid pseudopapillary neoplasm, each with its own characteristics.

Some key points about cystic neoplasms and rare malignancies:

  1. Cystic neoplasms can be serous or mucinous, with different malignant potentials.
  2. Rare pancreatic tumors often require specialized diagnostic approaches.
  3. Treatment plans for these tumors can vary significantly based on their pathology and stage.

This includes PNETs, cystic neoplasms, and rare malignancies. We use a detailed evaluation, precise diagnosis, and tailored treatment plans to help our patients the best we can.

Multidisciplinary Care for Pancreatic Cancer

Multidisciplinary care is key in treating pancreatic cancer. At Liv Hospital, we focus on giving patients all-around support. We work with patients to create treatment plans that fit their needs.

Collaborative Treatment Approach

A team approach is vital in fighting pancreatic cancer. It involves many specialties like surgery, medicine, and radiation. This teamwork makes sure every part of a patient’s care is covered.

Our team crafts a treatment plan that suits each patient. We consider the cancer’s stage, the patient’s health, and their wishes.

Specialized Centers and Protocols

Treatment for pancreatic cancer works best in specialized centers. These places have the latest technology and expert staff. They stay updated with the newest treatment protocols.

Our hospital is a specialized center for pancreatic cancer. We offer advanced surgery, chemotherapy, and radiation. We stick to proven treatment protocols to help our patients the most.

Benefits of Multidisciplinary Care

Description

Comprehensive Support

Patients get care from a team of specialists, covering all health aspects.

Personalized Treatment Plans

Treatment plans are made to fit the individual patient’s needs and wishes.

Improved Outcomes

Working together leads to more effective treatments and better results for patients.

Frontiers in Pancreatic Cancer Research

Researchers are making big strides in understanding pancreatic cancer. They are focusing on genetics, molecular research, immunotherapy, and targeted treatments. These efforts are key to finding better ways to treat the disease.

Genetic and Molecular Breakthroughs

Studies have found important genetic mutations and molecular pathways in pancreatic cancer. These discoveries are changing how we diagnose and treat the disease.

  • Genetic Mutations: Genes like KRAS, TP53, and SMAD4 are often mutated in pancreatic cancer. This helps doctors decide on treatments.
  • Molecular Pathways: Knowing the molecular pathways helps find new targets for therapy.

Immunotherapy and Targeted Treatments

Immunotherapy and targeted treatments are showing promise against pancreatic cancer. They aim to boost the immune system and attack cancer cells directly.

Immunotherapy: Immunotherapies, like checkpoint inhibitors and cancer vaccines, are being tested to see if they can improve immune responses against tumors.

Early Detection Initiatives

Finding cancer early is vital for better outcomes. Researchers are working on new screening methods and biomarkers for early detection.

  1. Liquid biopsies are being looked at as a way to detect cancer early.
  2. Imaging techniques, like MRI and CT scans, are being improved to catch cancer sooner.

At Liv Hospital, we are dedicated to keeping up with these advancements. We want to give our patients the best treatments and technologies available.

Living with Pancreatic Cancer

Pancreatic cancer patients face unique challenges. Supportive care can greatly improve their quality of life. At our institution, we focus on a complete care approach, not just treating the disease.

Symptom Management and Supportive Care

Managing symptoms is key for pancreatic cancer patients. Our team creates personalized care plans for each patient. These plans cover pain management, nutritional support, and more.

Supportive care is not just about physical symptoms. It also includes emotional and psychological support. We offer various services to help patients deal with their diagnosis and treatment.

Psychological Support and Quality of Life

A pancreatic cancer diagnosis is tough for patients and their families. Psychological support is vital for emotional challenges. Our team provides emotional and psychological care to help patients keep their quality of life.

Despite challenges, recent statistics show a five-year survival rate of about 13% for pancreatic cancer.. Yet, with the right supportive care, patients can manage symptoms and improve their well-being.

Our team works hard to ensure each patient gets the care and support they need during their pancreatic cancer journey.

Conclusion

Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic cancer, making up over 92% of cases. We stress the need for early detection and a team approach to care.

The outlook for pancreatic cancer patients depends on several things. This includes the cancer’s stage when found and how well treatment works. Pancreatic adenocarcinoma is very aggressive and often found late.

We’re dedicated to top-notch healthcare and support for patients from around the world. Our team of experts works together to give personalized care. This care goes from the first diagnosis to treatment and after.

Knowing about pancreatic cancer risks, symptoms, and treatments helps patients make better choices. We urge readers to find reliable sources of information and care.

FAQ

What is pancreatic ductal adenocarcinoma (PDAC)?

Pancreatic ductal adenocarcinoma (PDAC) is a common type of pancreatic cancer. It starts in the ductal epithelium of the pancreas. This cancer is very aggressive and dangerous.

What are the symptoms of pancreatic cancer?

Symptoms of pancreatic cancer can be hard to spot early. They include abdominal pain, weight loss, jaundice, and changes in bowel movements. Because it often doesn’t show symptoms early, finding it early is tough.

What are the risk factors for developing pancreatic cancer?

Several factors increase the risk of pancreatic cancer. These include genetic mutations, family history, age, smoking, obesity, and certain diets. Knowing these can help find and prevent it early.

How is pancreatic cancer diagnosed?

Doctors use imaging tests like CT scans and MRI, blood tests, and biopsies to diagnose pancreatic cancer. Accurate diagnosis and staging are key to choosing the right treatment.

What are the treatment options for pancreatic cancer?

Treatments for pancreatic cancer include surgery, chemotherapy, radiation, and combinations of these. The treatment plan depends on the tumor’s stage, resectability, and the patient’s health.

Why is pancreatic cancer so deadly?

Pancreatic cancer is deadly because it grows fast, is often found late, and is hard to treat. Finding it early and improving treatments are key to better outcomes.

What is the survival rate for pancreatic cancer?

The five-year survival rate for pancreatic cancer varies by stage. While it’s low, better treatments and early detection are helping patients live longer.

What is the role of multidisciplinary care in pancreatic cancer treatment?

Multidisciplinary care is vital for treating pancreatic cancer. It involves a team of specialists like surgeons, oncologists, and radiologists. This ensures patients get the best care.

What are the latest advances in pancreatic cancer research?

Research has made big strides in pancreatic cancer. This includes genetic discoveries, immunotherapy, and targeted treatments. Early detection efforts are also underway to improve survival rates.

How can patients with pancreatic cancer manage their symptoms and improve their quality of life?

Patients can manage symptoms and improve life quality through supportive care. This includes pain management, nutrition support, and psychological counseling.

Reference List

  1. “SEER Cancer Stat Facts: Pancreas Cancer”
  2. “Pancreatic Cancer Facts”
  3. “Key Statistics About Pancreatic Cancer”
  4. “Pancreatic Cancer Diagnoses and Mortality Rates Climb; Five-Year Survival Rate for Pancreatic Cancer Stalls at 13%”
  5. “Common Cancers”


References

National Center for Biotechnology Information. Evidence-Based Medical Insight. Retrieved from

https://www.ncbi.nlm.nih.gov/books/NBK518996/

i

Medical Disclaimer

The content on this page is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider regarding any medical conditions.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

We're Here to Help.
Get in Touch

Send us all your questions or requests, and our
expert team will assist you.

Our Doctors

Assoc. Prof. MD. Evrim Duman Radiation Oncology

Assoc. Prof. MD. Evrim Duman

Liv Hospital Ulus
Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology

Asst. Prof. MD. Meltem Topalgökçeli Selam

Liv Hospital Ulus
Prof. MD. Duygu Derin Medical Oncology

Prof. MD. Duygu Derin

Liv Hospital Ulus
Prof. MD. Emre Merdan Fayda Radiation Oncology

Prof. MD. Emre Merdan Fayda

Liv Hospital Ulus
Prof. MD. Mehmet Hilmi Doğu Hematology

Prof. MD. Mehmet Hilmi Doğu

Liv Hospital Ulus
Liv Hospital Bahçeşehir
Prof. MD. Meral Günaldı Medical Oncology

Prof. MD. Meral Günaldı

Liv Hospital Ulus
Assoc. Prof. MD. Murat Ayhan Medical Oncology

Assoc. Prof. MD. Murat Ayhan

Liv Hospital Vadistanbul
Prof. MD.  Itır Şirinoğlu Demiriz Hematology

Prof. MD. Itır Şirinoğlu Demiriz

Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology

Prof. MD. Tülin Tıraje Celkan

Liv Hospital Vadistanbul
Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology

Assoc. Prof. MD. Erkan Kayıkçıoğlu

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Mine Dağgez Gynecological Oncology

Assoc. Prof. MD. Mine Dağgez

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Ozan Balakan Medical Oncology

Assoc. Prof. MD. Ozan Balakan

Liv Hospital Bahçeşehir
MD. Taylan Bükülmez Radiation Oncology

MD. Taylan Bükülmez

Liv Hospital Bahçeşehir
Op. MD. Alp Koray Kinter Gynecological Oncology

Op. MD. Alp Koray Kinter

Liv Hospital Bahçeşehir
Prof. MD. Nuri Faruk Aykan Medical Oncology

Prof. MD. Nuri Faruk Aykan

Liv Hospital Bahçeşehir
Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology

Prof. MD. Yasemin Altuner Torun

Liv Hospital Bahçeşehir
Spec. MD. Özlem Doğan Medical Oncology

Spec. MD. Özlem Doğan

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Emir Çelik Medical Oncology

Assoc. Prof. MD. Emir Çelik

Liv Hospital Topkapı
Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology

Assoc. Prof. MD. Muhammed Mustafa Atcı

Liv Hospital Topkapı
Prof. MD. İrfan Çiçin Medical Oncology

Prof. MD. İrfan Çiçin

Liv Hospital Topkapı
Assoc. Prof. MD.  Ramazan Öcal Hematology

Assoc. Prof. MD. Ramazan Öcal

Liv Hospital Ankara
Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology

Assoc. Prof. MD. Nazlı Topfedaisi Özkan

Liv Hospital Ankara
Prof. MD. Fikret Arpacı Medical Oncology

Prof. MD. Fikret Arpacı

Liv Hospital Ankara
Prof. MD. Gökhan Erdem Medical Oncology

Prof. MD. Gökhan Erdem

Liv Hospital Ankara
Prof. MD. Meral Beksaç Hematology

Prof. MD. Meral Beksaç

Liv Hospital Ankara
Prof. MD. Oral Nevruz Hematology

Prof. MD. Oral Nevruz

Liv Hospital Ankara
Prof. MD. Saadettin Kılıçkap Medical Oncology

Prof. MD. Saadettin Kılıçkap

Liv Hospital Ankara
Prof. MD. Sadık Muallaoğlu Medical Oncology

Prof. MD. Sadık Muallaoğlu

Liv Hospital Ankara
Spec. MD. Ender Kalacı Medical Oncology

Spec. MD. Ender Kalacı

Liv Hospital Ankara
Assoc. Prof. MD. Fadime Ersoy Dursun Hematology

Assoc. Prof. MD. Fadime Ersoy Dursun

Liv Hospital Gaziantep
Prof. MD. Fatih Teker Medical Oncology

Prof. MD. Fatih Teker

Liv Hospital Gaziantep
Spec. MD. ELXAN MEMMEDOV Medical Oncology

Spec. MD. ELXAN MEMMEDOV

Liv Bona Dea Hospital Bakü
Spec. MD. Ceyda Aslan Hematology

Spec. MD. Ceyda Aslan

Spec. MD. Elkhan Mammadov Medical Oncology

Spec. MD. Elkhan Mammadov

Spec. MD. Elmir İsrafilov Hematology

Spec. MD. Elmir İsrafilov

Spec. MD. Minure Abışova Eliyeva Hematology

Spec. MD. Minure Abışova Eliyeva

Spec. MD. Natavan Azizova Medical Oncology

Spec. MD. Natavan Azizova

Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 174 42 01